0간질환 치료제 시장 : 규모, 점유율, 동향 분석, 제품별, 질환별, 지역별, 부문 예측(2025-2033년)
Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1771740
리서치사
:
Grand View Research, Inc.
발행일
:
2025년 06월
페이지 정보
:
영문 150 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
간질환 치료제 시장의 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면 간질환 치료제 세계 시장 규모는 2033년까지 402억 9,000만 달러로 성장할 것으로 예상되며 , 2025-2033년의 CAGR은 7.9%를 보일 것으로 예측됩니다. 주요 촉진요인은 간세포 암과 같은 간질환 증가와 이러한 유형의 질병 환자의 방대한 미개척 요구입니다.
바이오테크놀러지 및 제약산업에 의한 연구개발에 대한 막대한 지출과 강력한 파이프라인의 이용 가능성은 향후 기간 동안 간질환 치료제 시장의 성장을 뒷받침하는 주요 요인으로 기대되고 있습니다.
시장은 제품과 지역으로 이분됩니다. 신제품이 급속히 출시되고 시장의 성장을 뒷받침하고 있습니다.
간질환 치료제 시장 보고서 하이라이트
만성 바이러스성 간염의 세계 유병률의 높이, HBV의 치료 기간의 길이, HCV DAAs의 비싼 가격 설정에 의해 2024년에는 항바이러스제 부문이 39.84%의 최대 매출 점유율로 시장을 독점했습니다.
간염부문은 2024년에 40.44%의 최대매출 점유율로 시장을 독점했습니다.
북미는 간질환의 유병률 상승, 인구의 고령화, 획기적인 치료법이 견인해, 2024년에는 세계 수익의 39.87%를 차지해, 간질환 치료제 시장에서 최대의 점유율을 차지했습니다.
아시아태평양의 간질환 치료제 시장은 B형 간염과 C형 간염의 높은 유병률, NAFLD 환자 증가, 헬스케어 인프라의 개선에 의해 예측 기간 중에 9.19%의 연평균 복합 성장률(CAGR)로 가장 빠르게 성장할 것으로 예측됩니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 간질환 치료제 시장의 변수, 동향, 범위
시장 계통의 전망
시장 역학
시장 성장 촉진요인 분석
시장 성장 억제요인 분석
비즈니스 환경 분석
산업 분석 - Porter's Five Forces 분석
PESTLE 분석
파이프라인 분석
특허 만료 분석
가격 분석
제4장 간질환 치료제 시장 : 제품 비즈니스 분석
제품 시장 점유율, 2025년과 2033년
제품 부문 대시보드
시장 규모와 예측, 제품별 동향 분석, 2021-2033년
항바이러스제
백신
화학요법
표적요법
면역억제제
면역글로불린
코르티코스테로이드
기타
제5장 간질환 치료제 시장 : 질환 비즈니스 분석
질병 시장 점유율, 2025년과 2033년
질병 부문 대시보드
시장 규모와 예측, 질환별 동향 분석, 2021-2033년
간염
자가면역질환
비알코올성 지방성 간질환(NAFLD)
암
유전성 질환
기타
제6장 간질환 치료제 시장 : 지역별, 추정 및 예측 분석
지역별 시장 점유율 분석, 2025년과 2033년
지역별 시장 대시보드
시장 규모와 예측 동향 분석, 2021-2033년
북미
국가별, 2021-2033년
미국
캐나다
멕시코
유럽
영국
독일
프랑스
이탈리아
스페인
덴마크
스웨덴
노르웨이
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카
사우디아라비아
아랍에미리트(UAE)
쿠웨이트
제7장 경쟁 구도
참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
Gilead Sciences, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi
GSK plc
SHW
영문 목차
Liver Disease Therapeutics Market Growth & Trends:
The global liver disease therapeutics market size is expected to be valued at USD 40.29 billion by 2033, registering a CAGR of 7.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.
Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.
The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.
Liver Disease Therapeutics Market Report Highlights:
The antiviral drugs segment dominated the market with the largest revenue share of 39.84% in 2024 due to the high global prevalence of chronic viral hepatitis, long treatment durations for HBV, and premium pricing for HCV DAAs.
The hepatitis segment dominated the market with the largest revenue share of 40.44% in 2024, attributed to the widespread burden of chronic hepatitis and the clinical success of antiviral treatments, the hepatitis segment remains a major market driver.
North America held the largest share of the liver disease therapeutics market in 2024, accounting for 39.87% of global revenue, driven by the rising prevalence of liver disease, aging populations, and breakthrough therapies.
The liver disease therapeutics market in Asia Pacific is projected to grow at the fastest CAGR of 9.19% over the forecast period, fueled by the high prevalence of hepatitis B and C, rising NAFLD cases, and improving healthcare infrastructure.
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR's Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Liver Disease Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Liver Disease Therapeutics Market: Product Business Analysis
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Antiviral Drugs
4.4.1. Antiviral Drugs Market, 2021 - 2033 (USD Million)
4.5. Vaccines
4.5.1. Vaccines Market, 2021 - 2033 (USD Million)
4.6. Chemotherapy
4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
4.7. Targeted Therapy
4.7.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
4.8. Immunosuppressants
4.8.1. Immunosuppressants Market, 2021 - 2033 (USD Million)
4.9. Immunoglobulins
4.9.1. Immunoglobulins Market, 2021 - 2033 (USD Million)
4.10. Corticosteroids
4.10.1. Corticosteroids Market, 2021 - 2033 (USD Million)
4.11. Other Products
4.11.1. Other Products Market, 2021 - 2033 (USD Million)
Chapter 5. Liver Disease Therapeutics Market: Disease Business Analysis
5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
5.4. Hepatitis
5.4.1. Hepatitis Market, 2021 - 2033 (USD Million)
5.5. Autoimmune Diseases
5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
5.6. Non-alcoholic Fatty Liver Disease (NAFLD)
5.6.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market, 2021 - 2033 (USD Million)
5.7. Cancer
5.7.1. Cancer Market, 2021 - 2033 (USD Million)
5.8. Genetic Disorders
5.8.1. Genetic Disorders Market, 2021 - 2033 (USD Million)
5.9. Other Diseases
5.9.1. Other Diseases Market, 2021 - 2033 (USD Million)
Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2025 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2017 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Gilead Sciences, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. AbbVie Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Bristol-Myers Squibb Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. F. Hoffmann-La Roche Ltd
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Takeda Pharmaceutical Company Limited.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Johnson & Johnson Services, Inc.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Merck & Co., Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Novartis AG
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Pfizer Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Sanofi
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. GSK plc
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
관련자료
